Insights into Cardiogenic Shock from the Critical Care Cardiology Network

Sunday, March 8, 2026

8:32 AM - 8:40 AM EST

Location: International Ballroom East

Speaker(s)

David A. Morrow, MD

Director, Levine Cardiac Intensive Care Unit
Brigham and Women's Hospital

Disclosure(s): 4TEEN4: Grant/Research Support (Ongoing); Abbott Labs: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Abiomed: Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); Anthos Therapeutics: Grant/Research Support (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); Daiichi Sankyo: Grant/Research Support (Ongoing); Merck & Co.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Novartis Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Ongoing); Regeneron Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Roche Diagnostics: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)

Disclosure(s):

David A. Morrow, MD: 4TEEN4: Grant/Research Support (Ongoing); Abbott Labs: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Abiomed: Grant/Research Support (Ongoing); Amgen: Grant/Research Support (Ongoing); Anthos Therapeutics: Grant/Research Support (Ongoing); AstraZeneca: Grant/Research Support (Ongoing); Daiichi Sankyo: Grant/Research Support (Ongoing); Merck & Co.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Novartis Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Pfizer: Grant/Research Support (Ongoing); Regeneron Pharmaceuticals Inc.: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Roche Diagnostics: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)